U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07643038) titled 'Treatment Strategy for Patients With RA-ILD' on June 07.
Brief Summary: This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Rheumatoid Arthritis Associated Interstitial Lung Disease
Intervention:
DRUG: Tocilizumab
Tocilizumab will be administered intravenously at a dose of 8 mg/kg every 4 weeks in addition to stable background csDMARD therapy maintained throughout the study period.
DRUG: Telitacicept
Telita...